CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Capital Expenditures Growth by Quarter and Year

Atara Biotherapeutics Inc 's Capital Expenditures results by quarter and year




ATRA Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 4.20 4.17 9.70
III Quarter September - 1.49 4.50 6.19
II Quarter June - 0.74 7.45 3.14
I Quarter March 1.33 0.80 19.81 1.21
FY   1.33 7.23 35.93 20.24



ATRA Capital Expenditures first quarter 2020 Y/Y Growth Comment
Atara Biotherapeutics Inc achieved in the first quarter, above Company average Capital Expenditures rise of 66.63% year on year, to $ 1.33 millions.

Looking into first quarter results within Biotechnology & Drugs industry 7 other companies have achieved higher Capital Expenditures growth. While Atara Biotherapeutics Inc ' s Capital Expenditures jump of 66.63% ranks overall at the positon no. 186 in the first quarter.




ATRA Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - 0.72 % -57.01 % 602.9 %
III Quarter September - -66.89 % -27.3 % 725.33 %
II Quarter June - -90.07 % 137.26 % 252.81 %
I Quarter March 66.63 % -95.96 % 1537.19 % 348.15 %
FY   - -79.88 % 77.52 % 515.2 %

Financial Statements
Atara Biotherapeutics Inc 's first quarter 2020 Capital Expenditures $ 1.33 millions ATRA's Income Statement
Atara Biotherapeutics Inc 's first quarter 2019 Capital Expenditures $ 0.80 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Capital Expenditures Growth >>


ATRA Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - 181.88 % -7.33 % 56.7 %
III Quarter September - 101.35 % -39.6 % 97.13 %
II Quarter June - -7.5 % -62.39 % 159.5 %
I Quarter March -68.26 % -80.82 % 104.23 % -12.32 %
FY (Year on Year)   - -79.88 % 77.52 % 515.2 %




Capital Expenditures first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #8
Healthcare Sector #38
Overall #186

Capital Expenditures Y/Y Growth Statistics
High Average Low
9.37 % -15.69 % -39.68 %
(Mar 31 2020)   (Jun 30 2019)
Capital Expenditures first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #8
Healthcare Sector #38
Overall #186
Capital Expenditures Y/Y Growth Statistics
High Average Low
9.37 % -15.69 % -39.68 %
(Mar 31 2020)   (Jun 30 2019)

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Atara Biotherapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 126.23 % -100 %
(Dec 31 2015)  


ATRA's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2020 Atara Biotherapeutics Inc disclosed fall in Capital Expenditures sequentially by -68.26% to $ 1.33 millions, from $ 4.20 millions declared in the previous reporting period.

When you look into present downturn at the I. Quarter, you should presume, that frequently I. Quarter performance emerge weaker relative to the forth quarter

Within Biotechnology & Drugs industry 20 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 817.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #21
Healthcare Sector #106
Overall #817
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #21
Healthcare Sector #106
Overall #817
Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 126.23 % -100 %
(Dec 31 2015)  


ATRA's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2020 Atara Biotherapeutics Inc reported fall in Capital Expenditures sequentially by -68.26% to $ 1.33 millions, from $ 4.20 millions released in the previous reporting period.

As we analyse present shortcoming in the I. Quarter 2020, we suppose to assume, that usually I. Quarter 2020 results appear to be sluggish then in the preciding period

Within Biotechnology & Drugs industry 20 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 817.


Atara Biotherapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
Cumulative Capital Expenditures 12 Months Ending $ 6.27 $ 9.90 $ 7.19 $ 10.20 $ 0.00
Y / Y Capital Expenditures Growth (TTM) -62.93 % -76.11 % -82.66 % -76.36 % -
Year on Year Capital Expenditures Growth Overall Ranking # 1412 # 0 # 2253 # 0 # 334
Seqeuential Capital Expenditures Change (TTM) 9.37 % -2.94 % -29.52 % -39.68 % -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 186 # 0 # 2900 # 0 # 1735




Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2019. If the fiscal year would end in Mar 31 2020, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -62.93% year on year to $6 millions.

In the Healthcare sector 195 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 1412.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
9.37 %
-15.69 %
-39.68 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 8
Healthcare Sector # 196
Overall # 1412

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-62.93 %
-74.51 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 38
S&P 500 # 186
Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2019. If the fiscal year would end in Mar 31 2020, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -62.93% year on year to $6 millions.

In the Healthcare sector 195 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 1412.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
9.37 %
-15.69 %
-39.68 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 8
Healthcare Sector # 196
Overall # 1412

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-62.93 %
-74.51 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 38
S&P 500 # 186




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ATRA's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ATRA's Competitors
Capital Expenditures Growth for Atara Biotherapeutics Inc 's Suppliers
Capital Expenditures Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2020
Cryolife Inc   112.65 %$ 112.647 millions
Irhythm Technologies Inc   108.26 %$ 108.257 millions
Durect Corp  107.58 %$ 107.576 millions
Axonics Modulation Technologies Inc   104.00 %$ 104.000 millions
Seattle Genetics Inc  101.50 %$ 101.500 millions
Manhattan Scientifics Inc  100.00 %$ 100.000 millions
Cyclacel Pharmaceuticals Inc   100.00 %$ 100.000 millions
Repro Med Systems Inc  99.39 %$ 99.391 millions
Motus Gi Holdings Inc   97.73 %$ 97.727 millions
Sientra Inc   97.70 %$ 97.705 millions
Conformis Inc  95.11 %$ 95.112 millions
Xenon Pharmaceuticals Inc   93.13 %$ 93.134 millions
Adverum Biotechnologies Inc   92.59 %$ 92.589 millions
Opko Health Inc   91.88 %$ 91.883 millions
Alpha Pro Tech Ltd  89.47 %$ 89.474 millions
Athenex Inc   89.11 %$ 89.107 millions
Resmed Inc   88.93 %$ 88.932 millions
Regenxbio Inc   88.59 %$ 88.595 millions
Bio techne Corp  88.47 %$ 88.467 millions
Xtant Medical Holdings Inc   88.32 %$ 88.321 millions
Chembio Diagnostics Inc   86.72 %$ 86.723 millions
Tricida Inc   86.53 %$ 86.528 millions
Plus Therapeutics Inc   83.33 %$ 83.333 millions
Evolus Inc   82.26 %$ 82.260 millions
Arcturus Therapeutics Holdings Inc   82.05 %$ 82.051 millions
Apollo Endosurgery inc   79.66 %$ 79.661 millions
Xencor Inc  78.10 %$ 78.104 millions
Quest Diagnostics Inc  76.60 %$ 76.596 millions
Alector Inc   75.67 %$ 75.665 millions
Teladoc Health inc   75.33 %$ 75.329 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SGLB's Profile

Stock Price

SGLB's Financials

Business Description

Fundamentals

Charts & Quotes

SGLB's News

Suppliers

SGLB's Competitors

Customers & Markets

Economic Indicators

SGLB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071